Results 151 to 160 of about 696,518 (307)

Epicutaneous immunotherapy

Allergologia et Immunopathologia, 2017
S, Scheurer, M, Toda
openaire   +2 more sources

Biomimetic Nanovaccine Integrating Dendritic Cell Exosomes with Tumor Cell Membranes for Sustained Prophylaxis Against Glioblastoma

Advanced Functional Materials, EarlyView.
We have developed DEX/GM, an all‐natural, personalizable hybrid vaccine designed by coating dendritic cell‐derived exosomes (DEX) onto tumor cell membranes (GM) for sustained prophylaxis against glioblastoma (GBM). ABSTRACT Glioblastoma (GBM), one of the most aggressive and lethal brain tumors, remains incurable with a poor clinical prognosis.
Shanshan Li, Dongya Zhang, Shiyu Wang, Changhe Pang, Meng Zheng, Bingyang Shi, Yan Zou   +6 more
wiley   +1 more source

Assessment of Perceived Knowledge and Beliefs Toward Cancer Immunotherapy Among Regional Healthcare Providers. [PDF]

Cureus
Ismail A, Alnasr AA, Alamer BS, Albahli G, Alharbi RH, Alsawyan S, Ibrahim ES.   +6 more
europepmc   +1 more source

A complex immunological idiotypic network for maintenance of tolerance

Frontiers in Immunology, 2014
Véronique eTHOMAS-VASLIN, Véronique eTHOMAS-VASLIN, Véronique eTHOMAS-VASLIN   +2 more
doaj   +1 more source

Poly(lactic‐co‐glycolic acid) Nanoparticles for IL‐12 Self‐Amplifying RNA Delivery in Glioblastoma Models

Advanced Functional Materials, EarlyView.
xxxx. ABSTRACT Glioblastoma (GBM) remains one of the most lethal brain cancers, with median survival rarely exceeding 15 months after diagnosis. Interleukin‐12 (IL‐12) is a potent immunostimulatory cytokine capable of reshaping the tumor microenvironment (TME), yet its clinical translation is hindered by systemic toxicity and short half‐life. RNA‐based
Fatima Hameedat, Johan Sebastian Lopez‐Parra, Willem M. H. Hoogaars, Emma Dijkstra, Cynthia Huang, Irafasha C. Casmil, Anna K. Blakney, Peter Olinga, Barbara Rothen‐Rutishauser, Hélder A. Santos, Alke Petri‐Fink, Flávia Sousa   +11 more
wiley   +1 more source

Psychometric validation of Chinese version of the immunotherapy of the M.D. Anderson Symptom Inventory for Early-Phase Trials module in a multi-cancer cohort. [PDF]

Front Immunol
Fan T, Wu L, Lacuo Z, Liu Y, Wu X.
europepmc   +1 more source

Light Activated Induction of Cuproptosis in Resistant Cancer Cells Using Polymeric BODIPY Nanoparticles for Photoactivated Chemotherapy

Advanced Functional Materials, EarlyView.
This article presents a photo‐responsive nanoparticle platform that precisely triggers copper‐dependent cuproptotic cell death in (drug‐resistant) cancer cells. The system remains stable and inactive in the dark but releases cytotoxic species upon red‐light irradiation, achieving potent activity in drug‐resistant breast cancer cells.
Ricarda Zimmermann, Nicolás Montesdeoca, Johannes Karges   +2 more
wiley   +1 more source

Navigating Immunotherapy Resistance: The Role of Cross-Line Strategies in Cancer Treatment. [PDF]

J Clin Med
Kang Y, Zhen H, Wang J, Lin H, Cao B.
europepmc   +1 more source

Establishing a Model Precursor System: Over a Decade of Research on Carbon Dots from the Citric Acid‐Urea System

Advanced Functional Materials, EarlyView.
The citric acid/urea (CA‐Urea) precursor system offers a versatile, scalable route to carbon dots with tunable luminescence and multifunctionality. Mechanistic insights into precursor chemistry and reaction parameters have enabled doping, surface modification, and hybridization strategies, yielding CDs for luminescent devices, sensing, catalysis ...
Yupeng Liu, Zhiqi Cai, Xiangxin Sun, Hanyi Zhang, Yiming Hao, Jun Wu, Zekun Yan, Xue Wu, Yiqi Liang, Liming Wang, Songnan Qu   +10 more
wiley   +1 more source

Exploration of Optimal Synergistic Treatment Strategies of Postoperative Radiotherapy and Immunotherapy in Early-Stage Breast Cancer. [PDF]

Cancers (Basel)
Shang Q, Wang H, Zhuang Y, Plichta JK, Thomas SM, Ouyang M, Luo S, Wang X.   +7 more
europepmc   +1 more source